OBJECTIVE Diabetic nephropathy(DN)has been one of the most common complications of diabetes and the leading cause of end-stage renal disease.Glomerular hyperfiltrationis central in earlystage of DN and leads to the pr...OBJECTIVE Diabetic nephropathy(DN)has been one of the most common complications of diabetes and the leading cause of end-stage renal disease.Glomerular hyperfiltrationis central in earlystage of DN and leads to the progression of renal architectonic and functional abnormalities.Salvianolic acid A(SalA)has been proved to protect diabetic complications such as hepatic fibrosis and neuropathy.The present study was designed to investigate the effects of SalA on glomerular endothelial dysfunctionand diabetic nephropathy.METHODS Primary glomerular endothelial cells were subjected to assess permeability under injury of advanced glycation end-products(AGEs).AGEs-induced changes of Rho A/ROCK pathway and cytoskeleton rearrangement were assessed bywestern blotandimmunofluorescence.The beneficial effects of SalA on diabetic nephropathy were investigated in a rat model induced by high-fat and high-glucose diet combined with low dose of streptozocin(35 mg·kg^(-1),ip).Renal function and architectonic changes were evaluated by biochemical assay and PAS staining.RESULTS SalA 3μMameliorated AGEs-induced glomerular endothelial permeability(P<0.05)and suppressed rearrangement of cytoskeleton through inhibiting AGE-RAGE-Rho A/ROCK pathway.SalA1 mg·kg^(-1)markedly reduced endothelium loss(P<0.01)and glomerular hyperfiltration(P<0.05)in diabetic kidney.Subsequently,SalA 1 mg·kg^(-1) suppressed glomerular hypertrophy and mesangial matrix expansion,eventually reduced 24 h-urinary albumin and ameliorated renal function by decreasing blood urine nitrogen(BUN),serum creatinine(Scr)and serum n-acetyl-β-d-glucosaminidase(NAG).AGEs-RAGE-Nox4-induced oxidative stress was suppressed by the treatment of SalA 1 mg·kg^(-1).CONCLUSION SalA ameliorated AGEs-induced glomerular endothelial hyperpermeability,and effectively protected against early-stage diabetic nephropathy by reducing hyperfiltration and alleviating renal structural deterioration through inhibiting AGEs and its downstream pathway.Thus,SalA might be a promising therapeutic agent for the treatment of diabetic nephropathy.展开更多
Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From J...Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From January 2016 to October 2017, 36 cases with acute myeloid leukemia were selected as AML group. After 1-2 courses of standard chemotherapy, 27 cases with complete remission were selected as complete remission group, 9 cases without improvement as a group. In the same period, 20 healthy patients were selected as the healthy control group. The expression levels of sPD-L1 and VEGF were detected by enzyme-linked immunoassay (ELISA).Results: The expression of sPD-L1 and VEGF in serum of the initial and unrelieved AML patients was significantly higher than that in the healthy control group, and the difference was statistically significant. After 1-2 courses of standard chemotherapy, the expression of sPD-L1 and VEGF in the serum of patients with complete remission was significantly lower than that in the initial treatment group, and the difference was statistically significant. There was no statistically significant difference between the total relief group and the control group. There is a significant positive correlation between the two expressions. Conclusions: The high expression of sPD-L1and VEGF in serum may be related to the occurrence, development and prognosis of AML. Therefore, the joint detection of sPD-L1 and VEGF is of some significance to the early diagnosis, monitoring efficacy and prognosis of AML patients.展开更多
基金supported by National Nature Science Foundation of China(81770847)CAMS Innovation Fund for Medical Sciences(CIFMS)(2016-I2M-3-007,2016-I2M-1-010)National Key Research and Development Plan(2016YFC1000905)
文摘OBJECTIVE Diabetic nephropathy(DN)has been one of the most common complications of diabetes and the leading cause of end-stage renal disease.Glomerular hyperfiltrationis central in earlystage of DN and leads to the progression of renal architectonic and functional abnormalities.Salvianolic acid A(SalA)has been proved to protect diabetic complications such as hepatic fibrosis and neuropathy.The present study was designed to investigate the effects of SalA on glomerular endothelial dysfunctionand diabetic nephropathy.METHODS Primary glomerular endothelial cells were subjected to assess permeability under injury of advanced glycation end-products(AGEs).AGEs-induced changes of Rho A/ROCK pathway and cytoskeleton rearrangement were assessed bywestern blotandimmunofluorescence.The beneficial effects of SalA on diabetic nephropathy were investigated in a rat model induced by high-fat and high-glucose diet combined with low dose of streptozocin(35 mg·kg^(-1),ip).Renal function and architectonic changes were evaluated by biochemical assay and PAS staining.RESULTS SalA 3μMameliorated AGEs-induced glomerular endothelial permeability(P<0.05)and suppressed rearrangement of cytoskeleton through inhibiting AGE-RAGE-Rho A/ROCK pathway.SalA1 mg·kg^(-1)markedly reduced endothelium loss(P<0.01)and glomerular hyperfiltration(P<0.05)in diabetic kidney.Subsequently,SalA 1 mg·kg^(-1) suppressed glomerular hypertrophy and mesangial matrix expansion,eventually reduced 24 h-urinary albumin and ameliorated renal function by decreasing blood urine nitrogen(BUN),serum creatinine(Scr)and serum n-acetyl-β-d-glucosaminidase(NAG).AGEs-RAGE-Nox4-induced oxidative stress was suppressed by the treatment of SalA 1 mg·kg^(-1).CONCLUSION SalA ameliorated AGEs-induced glomerular endothelial hyperpermeability,and effectively protected against early-stage diabetic nephropathy by reducing hyperfiltration and alleviating renal structural deterioration through inhibiting AGEs and its downstream pathway.Thus,SalA might be a promising therapeutic agent for the treatment of diabetic nephropathy.
文摘Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From January 2016 to October 2017, 36 cases with acute myeloid leukemia were selected as AML group. After 1-2 courses of standard chemotherapy, 27 cases with complete remission were selected as complete remission group, 9 cases without improvement as a group. In the same period, 20 healthy patients were selected as the healthy control group. The expression levels of sPD-L1 and VEGF were detected by enzyme-linked immunoassay (ELISA).Results: The expression of sPD-L1 and VEGF in serum of the initial and unrelieved AML patients was significantly higher than that in the healthy control group, and the difference was statistically significant. After 1-2 courses of standard chemotherapy, the expression of sPD-L1 and VEGF in the serum of patients with complete remission was significantly lower than that in the initial treatment group, and the difference was statistically significant. There was no statistically significant difference between the total relief group and the control group. There is a significant positive correlation between the two expressions. Conclusions: The high expression of sPD-L1and VEGF in serum may be related to the occurrence, development and prognosis of AML. Therefore, the joint detection of sPD-L1 and VEGF is of some significance to the early diagnosis, monitoring efficacy and prognosis of AML patients.
